Vertex Pharmaceuticals (VRTX) Short term Debt (2009 - 2016)

Vertex Pharmaceuticals' Short term Debt history runs 6 years deep, the most recent figure standing at $300.0 million for Q4 2016.

• In Q4 2016, Short term Debt rose 320.78% year-over-year to $300.0 million; the TTM figure through Dec 2016 stood at $300.0 million (up 320.78% YoY), while the FY2016 annual figure was $300.0 million, up 320.78% from the prior year.
• Short term Debt was $300.0 million for Q4 2016 at Vertex Pharmaceuticals, up from $297.8 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $300.0 million in Q4 2016 to a low of $14.2 million in Q4 2014.
• Historically, Short term Debt has averaged $140.3 million across 3 years, with a median of $108.8 million in 2015.
• Biggest YoY gain for Short term Debt was 416.82% in 2016; the steepest drop was 320.78% in 2016.
• A 3-year view of Short term Debt shows it stood at $14.2 million in 2014, then soared by 401.87% to $71.3 million in 2015, then jumped by 320.78% to $300.0 million in 2016.
• The last three Short term Debt figures came in at $300.0 million (Q4 2016), $297.8 million (Q3 2016), and $221.6 million (Q2 2016), per Business Quant data.